



Innoviva to Participate in Upcoming Investor Conferences

September 2, 2026

BURLINGAME, Calif.--(BUSINESS WIRE)--Sep. 2, 2026-- Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:

Citi's 2026 Biopharma Back to School Conference

Format: 1x1 meetings

Date: Wednesday, September 9, 2026

Cantor Global Healthcare Conference

Format: Fireside chat

Date: Thursday, September 10, 2026

Time: 8:00 a.m. Eastern Time

H.C. Wainwright 28th Annual Global Investment Conference

Format: Presentation

Date: Monday, September 14, 2026

Time: 12:00 p.m. Eastern Time

Morgan Stanley 24th Annual Global Healthcare Conference

Format: 1x1 meetings

Date: Tuesday, September 15, 2026

A live webcast of the presentations can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at <https://investor.inva.com/presentations-events>. An archived replay of the webcasts will be available following each presentation date.

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus*, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVERTA (ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zotiloflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVERTA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260902630238/en/>

Investors and media contact

Irwin Tendler

Head of Investor Relations

Executive Director, Corporate Development

investors.relations@inva.com

Source: Innoviva, Inc.